D
David A. Garcia
Researcher at University of Washington
Publications - 227
Citations - 19783
David A. Garcia is an academic researcher from University of Washington. The author has contributed to research in topics: Warfarin & Apixaban. The author has an hindex of 45, co-authored 207 publications receiving 16799 citations. Previous affiliations of David A. Garcia include University of New Mexico.
Papers
More filters
Journal ArticleDOI
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger,John H. Alexander,Renato D. Lopes,Elaine M. Hylek,Michael G. Hanna,Hussein R. Al-Khalidi,Jack Ansell,Dan Atar,Alvaro Avezum,M. Cecilia Bahit,Rafael Diaz,J. Donald Easton,Justin A. Ezekowitz,Greg C. Flaker,David A. Garcia,Margarida Geraldes,Bernard J. Gersh,Sergey P. Golitsyn,Shinya Goto,Antonio G. Hermosillo,Stefan H. Hohnloser,John D. Horowitz,Puneet Mohan,Petr Jansky,Basil S. Lewis,Jose Lopez-Sendon,Prem Pais,Alexander Parkhomenko,Jun Zhu,Lars Wallentin +29 more
TL;DR: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.
Journal ArticleDOI
Prevention of VTE in Nonorthopedic Surgical Patients : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Michael K. Gould,David A. Garcia,Sherry M. Wren,Paul J. Karanicolas,Juan I. Arcelus,John A. Heit,Charles M. Samama +6 more
TL;DR: In this article, the authors developed recommendations for thromboprophylaxis in nonorthopedic surgical patients by using systematic methods as described in Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines.
Journal ArticleDOI
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob,Nick van Es,Peter Verhamme,Marc Carrier,Marcello Di Nisio,David A. Garcia,Michael A. Grosso,Ajay K. Kakkar,Michael J. Kovacs,Michele Mercuri,Guy Meyer,Annelise Segers,Minggao Shi,Tzu-Fei Wang,Erik Yeo,George Zhang,Jeffrey I. Zwicker,Jeffrey I. Weitz,Harry R. Büller +18 more
TL;DR: Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding during the 12 months after randomization, regardless of treatment duration.
Journal ArticleDOI
Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
TL;DR: Three additional parenteral direct thrombin inhibitors and danaparoid are approved as alternatives to heparin in patients with HIT, and fondaparinux-associated HIT or osteoporosis is unlikely to occur.
Journal ArticleDOI
Diagnosis and Management of the Antiphospholipid Syndrome.
David A. Garcia,Doruk Erkan +1 more
TL;DR: The immune response to antiphospholipid antibodies can induce endothelial-cell, complement, platelet, neutrophil, and monocyte activation, leading to thrombosis, renal failure, heart valve disea...